UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status
Unique ID issued by UMIN C000000143
Receipt No. R000000181
Scientific Title A combination phase I study of topotecan with cisplatin for elderly small cell lung cancer
Date of disclosure of the study information 2005/09/08
Last modified on 2005/09/08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A combination phase I study of topotecan with cisplatin for elderly small cell lung cancer
Acronym A combination phase I study of topotecan with cisplatin for elderly small cell lung cancer
Scientific Title A combination phase I study of topotecan with cisplatin for elderly small cell lung cancer
Scientific Title:Acronym A combination phase I study of topotecan with cisplatin for elderly small cell lung cancer
Region
Japan

Condition
Condition small cell lung cancer
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To estimate the maximum tolerable dose and recommended dose of cisplatin and topotecan, and to determine the efficacy and safety of the combination topotecan and cisplatin in patients with SCLC
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase I

Assessment
Primary outcomes Decision of the recommended dose of cisplatin and topotecan
Key secondary outcomes Determination of dose limited toxicity and response and safety of the combination of topotecan and cisplatin

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Topotecan: 0.6, 0.8, 1.0, 1.2 mg/m2, day 1-3, every 3 weeks
Cisplatin: 25 mg/m2, day 1-3, every 3 weeks
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
70 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) SCLC
2) No prior treatment
3) Extended disease of limited disease with pleural effusion
4) age>=70 years,Performance status (PS) of 0 to 2
5) At least one measurable lesion
6) Adequate main organ functions
7) Estimation of at least 3 months survival
8) No limitation of use of topotecan and cisplatin
9) Written informed consent
Key exclusion criteria 1)Severe infection and complication (hemorrhage and heart disease etc.)
2)Intestinal pneumonia or lung fibrosis
3)Symptomatic brain metastasis
4)History of active other malignancy
5)History of severe drug allergic reaction
6)Pregnant women or women willing child-bearing
7)Men willing to have children
8)Uncontrolled diabetes
9)Uncontrolled pleural, cardiac, or abdominal effusion
10)Inadequate condition diagnosed by primary physician
Target sample size 28

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kenji Tamura MD
Organization Kinki University School of Medicine, Nara Hospital
Division name Department of Medical Oncology
Zip code
Address 1248-1, Otoda, Ikoma, Nara, 630-0293, Japan
TEL 0743-77-0880
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization Kinki University School of Medicine
Division name Department of Medical Oncology
Zip code
Address 377-2 Ohno-higashi, Osaka-Sayama,
TEL 072-366-0221
Homepage URL
Email

Sponsor
Institute Department of Medical Oncology,
Kinki University School of Medicine
Institute
Department

Funding Source
Organization Department of Medical Oncology,
Kinki University School of Medicine
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2005 Year 09 Month 08 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status
Date of protocol fixation
2004 Year 02 Month 16 Day
Date of IRB
Anticipated trial start date
2004 Year 03 Month 01 Day
Last follow-up date
2007 Year 03 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2005 Year 09 Month 08 Day
Last modified on
2005 Year 09 Month 08 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000181

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.